Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your diet shrink a fatty liver? new study tests three approaches

NCT ID NCT07304336

Disease control Sponsor: University of Turin, Italy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three dietary strategies—low-carb, Mediterranean, and standard nutritional advice—in 173 overweight adults with MASLD (fatty liver disease) over 6 months. Researchers measured changes in liver fat and damage using scans and blood tests. The goal was to see which diet works best for managing this liver condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dietary intervention (low-carbohydrate diet, Mediterranean diet, or standard nutritional recommendations)
What this could lead to
If successful, this could show that specific diets effectively reduce liver fat and damage in people with MASLD, offering practical dietary guidance.
What could go wrong
This is a completed trial with 173 participants, so results are limited in size and may not apply to everyone. Dietary adherence can vary, and the study is not blinded, which may introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

173 people

The number who actually took part.

Started

Feb 2022

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age ≥18 and \<75 years * BMI ≥25 and \<35 kg/m2 * not having previously received nutritional advice for the liver disease Exclusion Criteria: * other causes of liver disease (including viral, autoimmune, cholestatic, genetic, alcoholic, and drug-induced) * other diseases or conditions requiring specific dietary recommendations * a history of alcohol abuse * diabetes mellitus * pharmacological treatments potentially interfering with study outcomes (corticosteroids, glucagon-like-peptide 1 agonists, biologic drugs) * pregnancy or breastfeeding * inability to give written informed consent * life expectancy expected to be \<1 year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Digestive System Diseases metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASLD

Contacts and locations

Locations

  • AOU Città della Salute e della Scienza di Torino, University of Torino, Torino.

    Torino, Torino, 10126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.